JP2018529331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529331A5 JP2018529331A5 JP2018511416A JP2018511416A JP2018529331A5 JP 2018529331 A5 JP2018529331 A5 JP 2018529331A5 JP 2018511416 A JP2018511416 A JP 2018511416A JP 2018511416 A JP2018511416 A JP 2018511416A JP 2018529331 A5 JP2018529331 A5 JP 2018529331A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino acid
- mutation
- seq
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562213466P | 2015-09-02 | 2015-09-02 | |
| US62/213,466 | 2015-09-02 | ||
| PCT/EP2016/070654 WO2017037196A1 (en) | 2015-09-02 | 2016-09-01 | Stabilized viral class i fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020188363A Division JP2021045138A (ja) | 2015-09-02 | 2020-11-12 | 安定化したウイルスクラスｉ融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529331A JP2018529331A (ja) | 2018-10-11 |
| JP2018529331A5 true JP2018529331A5 (enExample) | 2019-08-08 |
| JP6975709B2 JP6975709B2 (ja) | 2021-12-01 |
Family
ID=56855456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511416A Active JP6975709B2 (ja) | 2015-09-02 | 2016-09-01 | 安定化したウイルスクラスｉ融合タンパク質 |
| JP2020188363A Pending JP2021045138A (ja) | 2015-09-02 | 2020-11-12 | 安定化したウイルスクラスｉ融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020188363A Pending JP2021045138A (ja) | 2015-09-02 | 2020-11-12 | 安定化したウイルスクラスｉ融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10538557B2 (enExample) |
| EP (2) | EP3344288A1 (enExample) |
| JP (2) | JP6975709B2 (enExample) |
| CN (1) | CN108025057B (enExample) |
| AU (2) | AU2016316723B2 (enExample) |
| CA (1) | CA2997181A1 (enExample) |
| WO (1) | WO2017037196A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3344291B1 (en) | 2015-09-03 | 2024-11-27 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| CN111148509A (zh) | 2017-07-24 | 2020-05-12 | 诺瓦瓦克斯股份有限公司 | 治疗呼吸系统疾病的方法和组合物 |
| SG11202009206QA (en) | 2018-03-19 | 2020-10-29 | Novavax Inc | Multivalent influenza nanoparticle vaccines |
| AU2019323115A1 (en) * | 2018-08-13 | 2021-01-28 | Janssen Vaccines & Prevention B.V. | Stabilized filovirus glycoprotein trimers |
| CN109142723B (zh) * | 2018-08-21 | 2021-07-13 | 苏州华益美生物科技有限公司 | 人类免疫缺陷病毒快速检测测试卡及其应用 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| CN115884786A (zh) | 2020-05-11 | 2023-03-31 | 杨森制药公司 | SARS-CoV-2疫苗 |
| MX2022014167A (es) | 2020-05-11 | 2023-02-14 | Janssen Pharmaceuticals Inc | Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada. |
| US20240189416A1 (en) | 2020-05-11 | 2024-06-13 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| JP2023527556A (ja) * | 2020-05-29 | 2023-06-29 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 操作されたコロナウイルススパイク（ｓ）タンパク質およびその使用方法 |
| CN111704657B (zh) * | 2020-06-16 | 2021-11-09 | 四川安可瑞新材料技术有限公司 | Hiv-2重组抗原及其制备方法、用途 |
| PH12022553417A1 (en) | 2020-07-06 | 2024-04-22 | Janssen Pharmaceuticals Inc | Stabilized corona virus spike protein fusion proteins |
| US20230270838A1 (en) * | 2020-08-02 | 2023-08-31 | Richard Ascione | Vaccine compositions for influenza viruses and methods of use |
| JP2024512766A (ja) * | 2021-03-30 | 2024-03-19 | ベイラー カレッジ オブ メディスン | 高力価ポリペプチドベースのタンパク質阻害のための方法および組成物 |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| CN116947982B (zh) * | 2023-07-12 | 2024-05-14 | 吉林大学 | 三条优势表位肽序列及其在流感病毒疫苗的应用 |
| WO2025051975A1 (en) * | 2023-09-06 | 2025-03-13 | Sanofi | Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| JP5809557B2 (ja) * | 2008-06-05 | 2015-11-11 | アブリンクス エン．ヴェー． | ウイルスのエンベロープタンパク質に指向性を有するアミノ酸配列、及びウイルス疾患の治療のためのこれを含むポリペプチド |
| PL3275892T3 (pl) * | 2011-05-13 | 2020-09-07 | Glaxosmithkline Biologicals S.A. | Przedfuzyjne antygeny RSV F |
| KR20140077169A (ko) * | 2011-09-30 | 2014-06-23 | 노바백스, 인코포레이티드 | 호흡기 세포 융합 바이러스에 대한 재조합 나노입자 ｒｓｖ ｆ 백신 |
| CN104066446B (zh) * | 2011-11-28 | 2017-10-03 | 扬森疫苗与预防公司 | 流感病毒疫苗及其用途 |
| RS58436B1 (sr) | 2013-04-25 | 2019-04-30 | Janssen Vaccines & Prevention Bv | Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi |
| US10058604B2 (en) * | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
-
2016
- 2016-09-01 EP EP16760463.6A patent/EP3344288A1/en not_active Withdrawn
- 2016-09-01 CN CN201680051120.1A patent/CN108025057B/zh active Active
- 2016-09-01 EP EP21200796.7A patent/EP4019044A3/en not_active Withdrawn
- 2016-09-01 WO PCT/EP2016/070654 patent/WO2017037196A1/en not_active Ceased
- 2016-09-01 JP JP2018511416A patent/JP6975709B2/ja active Active
- 2016-09-01 CA CA2997181A patent/CA2997181A1/en active Pending
- 2016-09-01 US US15/756,800 patent/US10538557B2/en active Active
- 2016-09-01 AU AU2016316723A patent/AU2016316723B2/en active Active
-
2019
- 2019-12-03 US US16/701,429 patent/US10711042B2/en active Active
-
2020
- 2020-11-12 JP JP2020188363A patent/JP2021045138A/ja active Pending
-
2021
- 2021-03-02 AU AU2021201330A patent/AU2021201330A1/en not_active Abandoned